How Ardelyx's Phase 3 ACCEL Trial for IBSRELA in CIC Will Impact Ardelyx (ARDX) Investors [Yahoo! Finance]
Ardelyx, Inc. (ARDX)
Last ardelyx, inc. earnings: 3/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ardelyx.com/investor-relations
Company Research
Source: Yahoo! Finance
adults with chronic idiopathic constipation, aiming to expand use beyond its existing irritable bowel syndrome with constipation indication. This move highlights Ardelyx's effort to broaden IBSRELA's clinical footprint in a condition affecting more than 34 million Americans, while navigating important safety considerations in pediatric populations. Next, we will examine how this Phase 3 ACCEL trial aimed at chronic idiopathic constipation reshapes Ardelyx's broader investment narrative. We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year . See the full list for free. For Ardelyx, the core investment case still revolves around execution on IBSRELA and XPHOZAH, potential profitability over the next few years, and how any possible Zydus transaction ultimately plays out. The new ACCEL Phase 3 trial in chronic idiopathic constipation adds another potential use for IBSRELA, but with enrollment running through 2026 and data expected in 2027, it doe
Show less
Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARDX alerts
High impacting Ardelyx, Inc. news events
Weekly update
A roundup of the hottest topics
ARDX
News
- Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results [Yahoo! Finance]Yahoo! Finance
- Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Ardelyx (NASDAQ:ARDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $17.00 price target on the stock.MarketBeat
- Is Ardelyx (ARDX) Pricing Reflect Its Strong Multi Year Share Price Performance [Yahoo! Finance]Yahoo! Finance
- First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELAGlobeNewswire
ARDX
Earnings
- 10/30/25 - Beat
ARDX
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/27/26 - Form 4
- 1/26/26 - Form 4
- ARDX's page on the SEC website